Study Design Type: Phase 2, double-blind, randomized, placebo-controlled study Participants: 338 adults (BMI 30 or BMI 27 with a coexisting condition) Groups: Retatrutide 1 mg, 4 mg, 8 mg, 12 mg (different initial doses 2 or 4 mg) and placebo Duration: 48 weeks (plus 4 weeks follow-up) Administration: subcutaneous, 1x weekly Primary endpoint: percentage change in body weight at week 24 Secondary endpoints: change in weight at week 48, 5%, 10%, 15% weight reduction
It commonly appears on the face, forehead, chest, upper back, and shoulders
Max Martin, Enhanceds twenty-nine-year-old C.E.O., would not disclose his personal enhancement protocol but explained that he takes six times the dosage of some of the athletes
belkeit und Kopfschmerzen dauerten jedoch noch eine Woche nach der Einnahme an